

1 **Xpert MTB/RIF Ultra resistant and MTBDR_{plus} susceptible rifampicin results in people with**
2 **tuberculosis: utility of FluoroType MTBDR and deep sequencing**

3 Yonas Ghebrekristos (MSc)^{1,2}, Aysha Ahmed (ND)², Natalie Beylis (MBBCH)³, Sarishna Singh
4 (MMed)^{1,2}, Christoffel Opperman (MMed)^{1,2,3}, Fahd Naufal (MPH)⁵, Megan Folkerts (MS)⁴, David
5 Engelthaler (PhD)⁴, Erick Auma (MSc)¹, Rouxjeane Venter (PhD)¹, Ghowa Booley (MMed)³, John
6 Metcalfe (PhD)⁵, Robin Warren (PhD)¹, Grant Theron (PhD)^{1†}

7 **Affiliations:**

8 ¹DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for
9 Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and
10 Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.

11 ²National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa.

12 ³Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town,
13 South Africa.

14 ⁴Translational Genomics Research Institute, Flagstaff, Arizona, USA.

15 ⁵University of California San Francisco, San Francisco, California, USA.

16 [†]**Corresponding author:** Prof Grant Theron, BMRI Building, 2nd Floor, Room, Faculty of Health
17 Sciences, Department of Molecular and Biology and Human Genetics, Francie van Zijl Drive,
18 Tygerberg Campus, Tygerberg 7505, South Africa.

19 E-mail: gtheron@sun.ac.za

20 **Keywords:** tuberculosis, diagnosis, rifampicin susceptibility, heteroresistance

21 **Summary** (249/250)

22 Background: Xpert MTB/RIF Ultra (Ultra)-detected rifampicin-resistant tuberculosis (TB) is often
23 programmatically confirmed using MTBDR*plus*. There are limited data on discordant results,
24 including re-tested using newer methods like FluoroType MTBDR (FT-MTBDR) and targeted deep
25 sequencing.

26 Methods: MTBDR*plus* rifampicin-susceptible isolates from people with Ultra rifampicin-resistant
27 sputum were identified from a South African programmatic laboratory. FT-MTBDR and single
28 molecule-overlapping reads deep (SMOR; *rpoB*, *inhA*, *katG*) on isolate DNA were done (SMOR
29 reference standard).

30 Findings: Between 01/04/2021-30/09/2022, 8% (109/1347) of Ultra rifampicin-resistant specimens
31 were MTBDR*plus*-susceptible. Of 89% (97/109) isolates with a sequenceable *rpoB*, SMOR resolved
32 most in favour of Ultra [79% (77/97)]. Sputum with lower mycobacterial load was associated with
33 Ultra false-positive resistance [46% (11/24) of “very low” Ultras had false-resistance vs. 12% (9/73;
34 $p=0.0004$) in those \geq “low”], as were Ultra heteroresistance calls (all wild type probes, ≥ 1 mutant
35 probe) [62% (23/37 vs. 25% (15/60) for Ultra without heteroresistance calls; $p=0.0003$]. Of the 91%
36 (88/97) of isolates successfully tested by FT-MTBDR, 55% (48/88) were FT-MTBDR rifampicin-
37 resistant and 45% (40/88) susceptible, translating to 69% (47/68) sensitivity and 95% (19/20)
38 specificity. In the 91% (99/109) of isolates with *inhA* and *katG* sequenced, 62% (61/99) were SMOR
39 isoniazid-susceptible.

40 Interpretation: When Ultra and MTBDR*plus* rifampicin results are discordant, Ultra is more likely to
41 be correct and FT-MTBDR agrees more with Ultra than MTBDR*plus*, however, lower load and the
42 Ultra heteroresistance probe pattern were risk factors for Ultra false rifampicin-resistant results. Most
43 people with Ultra-MTBDR*plus* discordant resistance results were isoniazid-susceptible. These data
44 have implications for drug-resistant TB diagnosis.

45 Funding: This work was supported by European & Developing Countries Trial Partnerships
46 (EDCTP2; RIA2020I-3305, CAGE-TB), National Institutes of Health (D43TW010350;
47 U01AI152087; U54EB027049; R01AI136894).

48 Introduction

49 Xpert MTB/RIF Ultra (Ultra; Cepheid, Sunnyvale, USA) is a widely used test for diagnosing
50 tuberculosis (TB) and detecting rifampicin-resistance. Endorsed by the WHO, Ultra has been an
51 essential screening tool in high-incidence countries, such as South Africa, where it has been used
52 routinely since 2011. At the time of this study, in the South African TB Control programme, if Ultra
53 detected rifampicin-resistance, a second specimen is typically cultured. The resulting TB isolate can
54 be tested with GenoType MTBDR*plus* VER 2.0 (MTBDR*plus*, Bruker-Hain Lifescience, Nehren,
55 Germany) which confirms the rifampicin-resistance and can additionally detect isoniazid resistance.
56 However, discrepancies between results obtained directly from the patient specimen and those from
57 cultured isolates or other molecular assays can occur, complicating both reporting and clinical
58 management. This discordance, which could be due to heteroresistance, can lead to poor outcomes,¹
59 patient distress and significant financial burdens due to delays and additional testing.

60 Although superseded in some settings by FluoroType MTBDR VER 2.0 (FT-MTBDR; Bruker-Hain
61 Lifescience, Nehren, Germany),^{2, 3} MTBDR*plus* is widely used for confirmatory drug susceptibility
62 testing (DST). Both Ultra and MTBDR*plus* target the *rpoB* rifampicin-resistant determining region
63 (RRDR) of *Mycobacterium tuberculosis* complex (MTBC). Reports from our high burden setting of
64 South Africa highlight discordance in ~ 7% of Xpert MTB/RIF (Xpert; Ultra's predecessor) resistant
65 samples, which were MTBDR*plus* rifampicin-susceptible.^{4, 5} Sub-optimal Xpert readouts, particularly
66 in the “very low” semi-quantification category, and probe delay have been linked to false-rifampicin-
67 resistance calls.⁶ However, this has not yet been studied in the context of Ultra. Aside from factors
68 like human error or cross-contamination, discordant results may also arise due to heteroresistance and
69 culture bias, as Ultra is performed directly on specimens while MTBDR*plus* is typically conducted on
70 cultured isolates.⁷⁻⁹

71 Two additional critical gaps exist. First, although Ultra itself does not directly report rifampicin
72 heteroresistance, probe melting temperatures have been suggested as a potential tool for inferring
73 heteroresistance (if a specific probe has melting temperatures corresponding to both wild-type and
74 mutant strains).¹⁰ However, the diagnostic accuracy of such Ultra's heteroresistance calls on clinical
75 specimens has not been evaluated. Second, it is unclear whether the level of discordance between
76 Ultra and FT-MTBDR, which utilizes LiquidArray technology to detect MTBC and mutations in
77 *rpoB*, *inhA*, and *katG* genes, is comparable to that observed with MTBDR*plus*.²

78 We sought to address these knowledge gaps in individuals identified programmatically as having
79 discordant rifampicin results (Ultra-resistant, MTBDR*plus*-susceptible). To ascertain true rifampicin
80 susceptibility status, we employed targeted deep sequencing with single molecule-overlapping reads
81 (SMOR) as a reference standard.^{7, 9} Additionally, we used FT-MTBDR as a comparator. Our study

82 also sought to identify test parameters associated with discordance, heteroresistance, and rifampicin
83 mono-resistance.

84 **Materials and methods**

85 Study design and setting

86 The study was conducted from 1 April 2021 to 30 September 2022, using patient specimens and their
87 corresponding isolates processed at the high-throughput National Health Laboratory Service (NHLS)
88 Greenpoint TB Laboratory (Cape Town, South Africa; ~60 000 TB tests per month).

89 Routine diagnostic algorithm

90 Following the diagnostic algorithm, healthcare workers collected two sputum samples an hour apart
91 from individuals with presumptive TB. Upon laboratory receipt, one specimen was arbitrarily selected
92 for testing with Ultra and processed according to the manufacturer's instructions.¹¹ If Ultra detected
93 MTBC and rifampicin-resistance, the second specimen was processed for mycobacterial culture using
94 the standard NALC-NaOH (1.25% final concentration) decontamination procedure and 0.5 ml
95 inoculated into a Mycobacterium Growth Indicator Tube 960 (MGIT960; Becton Dickinson
96 Diagnostic Systems, Sparks, USA) supplemented with polymyxin B (400 units/ml), amphotericin B
97 (40 µg/ml), nalidixic acid (160 µg/ml), trimethoprim (40 µg/ml) and azlocillin (40 µg/ml) (PANTA,
98 Becton Dickinson Diagnostic Systems) and incubated for ≤35 days. After a tube is automatically
99 flagged growth-positive, Ziehl-Neelsen (ZN) microscopy was performed to detect acid-fast bacilli
100 (AFB). If AFBs were observed, MTBDR_{plus} was conducted on the MGIT culture according to the
101 manufacturer's protocol, using the GenoScan instrument with semi-automated reading and manual
102 confirmation.¹² All MGIT isolates were stored at room temperature.

103 Discordant isolate selection and definition of Ultra heteroresistance results

104 We selected MTBDR_{plus} rifampicin-susceptible isolates from specimens collected concurrently with
105 those tested by Ultra (**Figure 1**). Patients were classified as Ultra heteroresistant based on the melting
106 temperature curve peaks for each *rpoB* probe as previously described.¹⁰ Briefly, if each probe
107 exhibited melting peaks corresponding to the wild-type temperature in addition to at least one *rpoB*
108 mutant melting peak, the result was designated heteroresistant (**Figure 2**).

109 FluoroType MTBDR

110 *DNA Extraction:* 500 µl of MGIT960 growth culture was treated with 167 µl of inactivation reagent
111 (room temperature, 30 min) and DNA was extracted using the GXT96 X2 Extraction Kit VER1.0
112 (Bruker-Hain Lifescience, Nehren, Germany) with the GenoXtract fleXT instrument (Bruker-Hain
113 Lifescience, Nehren, Germany), as per the manufacturer's instructions.¹³ With each extraction, saline
114 buffer and un-inoculated MGIT960 (supplemented with PANTA) were included as a negative control,
115 alongside the provided positive control.

116 *PCR*: Extracted DNA was amplified using the FluoroCycler XT (Bruker-Hain Lifescience, Nehren,
117 Germany) and analysed with the controls using FluoroSoftware XT-IVD (version 1.0.1.5.5.75;
118 Bruker-Hain Lifescience, Nehren, Germany).

119 Single Molecule Overlapping Reads (SMOR)

120 *DNA extraction*: Briefly, 100 µl of growth from the MGIT960 tube was heated at 100°C for 30 min,
121 as previously described.¹⁴

122 *Sequencing*: Primers were used to amplify *inhA*, *katG*, and *rpoB* resistance determining regions as
123 described (**Supplementary Material pp2**).¹⁵ A second PCR added adapters using a previously
124 published universal tail method. Samples were pooled and sequenced on an Illumina MiSeq (V3,
125 600bp paired-end chemistry). Multiple no template controls were used as quality control to ensure the
126 integrity of results.

127 *Bioinformatics*: The Amplicon Sequencing Analysis Pipeline (version 1.9; ASAP) was used,^{15, 16}
128 which requires overlapping forward and reverse reads to agree and uses read counts to report variant
129 frequency. Resistance calls were classified by ASAP into predefined categories based on the
130 percentage of reads with a known resistance associated variant (RAV) as “microheteroresistance”
131 (0.1-<5%), “macroheteroresistant” (5-95%) or “full resistant” (>95%).⁸ SMOR requires at least 10
132 paired reads at a locus to make a call. In this case, to call to 0.1%, 10,000 paired reads were required
133 for reporting. When multiple RAVs were detected in a single amplicon, ASAP was used to determine
134 whether they were on the same read as previously described¹⁷ and thus likely originate from a single
135 population (haplotype identification).

136 Statistical analysis and definitions

137 2×2 tables were used to calculate sensitivity and specificity with 95% confidence intervals (CIs, exact
138 binomial method) and using SMOR results as a reference standard for rifampicin and isoniazid. The
139 `prtesti` command (STATA 18, StataCorp) was used for comparisons between proportions. Results
140 were classified as successful if a test yielded a definitive resistant or susceptible result; outcomes
141 where MTBC was not detected, or results were uninterpretable were considered unsuccessful.¹⁸

142 Ethics

143 This study was done according to relevant guidelines and regulations, and approved by the Human
144 Research Ethics Committee, Division of Molecular and Human Genetics, Department of Biomedical
145 Sciences at Stellenbosch University, Cape Town, South Africa (S20/08/189) and the National Health
146 Laboratory Service Academic Affairs, Research and Quality Assurance, South Africa (PR2119347).
147 Permission was granted to access anonymised to-be-discarded residual samples collected as part of
148 routine diagnostic practice with waived informed consent.

149 Role of funding source

150 The funder of the study had no role in study design, data collection, data analysis, data interpretation,
151 or writing.

152 **Results**

153 Frequency of discordant rifampicin results

154 Between 01/04/2021-30/09/2022, 1623 patients with Ultra rifampicin-resistance were identified.
155 MTBDR_{plus} was performed on 91% (1483/1623) of these samples, with 91% (1347/1483) yielding
156 determinate results for rifampicin susceptibility. Of these, 8% (109/1347) were MTBDR_{plus}
157 rifampicin-susceptible, and hence discordant with Ultra (**Figure 1**).

158 Relationship between Ultra and SMOR rifampicin results

159 *RAV frequency:* Of 92% (100/109) Ultra-MTBDR_{plus} discordant isolates available for SMOR, 97%
160 (97/100) generated a successful result; 39% (38/97) were classified as full resistant, 19% (18/97)
161 macroheteroresistant, 21% (20/97) microheteroresistant, and the remainder 21% (20/97) had no
162 resistance-associated reads. Therefore, the positive predictive value (PPV) of Ultra rifampicin-
163 resistance for true rifampicin-resistance (as defined by a SMOR reference standard) was 79% (77/97),
164 with 21% (20/97) of Ultra results correspondingly being false-positive for rifampicin-resistance.
165 Lower Ultra-detected load (higher C_{Tmin}) was positively associated with false-positive results [median
166 (IQR) C_{Tmin} 29 (28-31) vs. 19 (18-25) in true positives; $p=0.0001$]. Specifically, in Ultra results with a
167 “very low” semi-quantitation category, 46% (11/24) had false resistance compared to 12% (9/73
168 $p=0.0004$) in those with a higher semi-quantitation category [when restricted to those with Ultra
169 heteroresistant patterns these were 75% (6/8) vs. 21% (6/29); $p=0.0037$] (**Table 1**).

170 Heteroresistance

171 Thirty-nine percent (38/97) of people had SMOR-detected heteroresistance and 38% (37/97) of Ultra
172 results exhibited heteroresistant probe patterns. Among these Ultra results, 67% (25/37) had SMOR-
173 detected resistance with two classified as resistant, 11 as macroheteroresistant, and 12 as
174 microheteroresistance; 12 were classified as susceptible by SMOR. Of the 60 Ultra results without
175 heteroresistant patterns, 87% (52/60) had SMOR-detected resistance with 37 classified as resistant,
176 seven as macroheteroresistant, and eight as microheteroresistant; eight were classified as susceptible
177 by SMOR. SMOR-detected heteroresistance was more common in Ultra-detected heteroresistance
178 isolates compared to those without Ultra-detected heteroresistance [62% (23/37) vs. 25% (15/60);
179 ($p=0.0003$)]. Ultra heteroresistance patterns therefore had 61% (23/38) sensitivity and 95% (37/39)
180 specificity for SMOR heteroresistance. Lastly, Ultra heteroresistance was more likely than Ultra non-
181 heteroresistance resistance results to be false-positive for rifampicin-resistance [PPV, 68% (25/37) vs
182 87% (52/60); $p=0.021$].

183 *Haplotyping:* Isolates from 21% (16/77) people had two or more *rpoB* mutations detected by SMOR.
184 Nineteen percent (3/16) had all mutant calls on the same read and the remaining 79% (13/16) had
185 mutations on separate reads, suggesting they were in separate strain subpopulations.

186 *Isoniazid susceptibility*

187 Thirty-eight of 99 (38%) samples demonstrated isoniazid resistance-associated mutations by SMOR
188 (22 resistant, 7 macroheteroresistant, 9 microheteroresistance; 61 susceptible); 55% (21/38) had *katG*
189 and 45% (17/38) *inhA* mutations by SMOR. Sensitivity and specificity for isoniazid resistance by
190 MTBDR*plus* were 53% (20/38) and 98% (60/61), respectively (**Supplementary Material Table 2**).
191 Among the isolates that were false MTBDR*plus* isoniazid-susceptible, 67% (12/18) had
192 heteroresistance (8 microheteroresistance). Heteroresistance was less frequent in MTBDR*plus*
193 isoniazid true positives, with 20% (4/20) being heteroresistant (3 macroheteroresistance). Notably, of
194 the 77 isolates that were SMOR rifampicin-resistant, 56% (43/77) were isoniazid-susceptible
195 (rifampicin mno-resistant).

196 *FluoroType MTBDR*

197 *Rifampicin*: From the usable rifampicin SMOR results, 91% (88/97) also had successful FT-MTBDR
198 results with 55% (48/88) resistant (Ultra-concordant) and 45% (40/88) susceptible (MTBDR*plus*-
199 concordant). FT-MTBDR sensitivity and specificity for rifampicin-resistance were 69% (47/68) and
200 95% (19/20), respectively (**Supplementary Material Table 2**). Amongst FT-MTBDR rifampicin-
201 susceptible isolates, 53% (21/40) were rifampicin-resistant via SMOR. Of these, 100% (21/21) had
202 heteroresistance (19 microheteroresistant) and in all 100% (47/47) SMOR rifampicin-resistant isolates
203 without heteroresistance were detected correctly by FT-MTBDR.

204 *Isoniazid*: From the 98 people with successful isoniazid FT-MTBDR and SMOR results, 72% (71/98)
205 were FT-MTBDR susceptible and 28% (27/98) FT-MTBDR resistant. FT-MTBDR sensitivity and
206 specificity for isoniazid resistance were 71% (27/38) and 100% (60/60); respectively
207 (**Supplementary Material Table 2**). Among FT-MTBDR isoniazid-susceptible isolates, 15% (11/71)
208 were isoniazid-resistant by SMOR. All of these, 100% (11/11) had heteroresistance (8
209 microheteroresistant) and 100% (22/22) SMOR isoniazid-resistant without heteroresistance were
210 detected correctly by FT-MTBDR. Among people with SMOR heteroresistance, FT-MTBDR
211 correctly detected resistance in 31% (5/16).

212 *Compared to MTBDRplus for isoniazid resistance*: 99 people had successful MTBDR*plus* and FT-
213 MTBDR results, 90% of which were concordant (19 resistant, 70 susceptible) and 10 discordant [8
214 FT-MTBDR resistant and MTBDR*plus* susceptible, 2 FT-MTBDR susceptible and MTBDR*plus*
215 resistance; SMOR supported the FT-MTBDR result in 90% (9/10) people]. The sensitivity of FT-
216 MTBDR for isoniazid resistance was better than MTBDR*plus* [53% (20/38) vs 71% (27/38);
217 $p=0.0983$], whereas specificity remained similar [98% (60/61) vs 100% (60/60); $p=0.3193$]
218 (**Supplementary Material Table 2**).

219 Discussion

220 To our knowledge, this study is the first to describe rifampicin susceptibility discordance between the
221 WHO-recommended rapid molecular tests Ultra and MTBDR*plus*. Our key findings are: 1) Most
222 discordance (79%) was from MTBDR*plus* not detecting rifampicin-resistance and 2) 69% of these
223 MTBDR*plus*-susceptible were detected as FT-MTBDR resistant, indicating FT-MTBDR has higher
224 sensitivity than MTBDR*plus*. However, 3) a substantial proportion with sequencing-detected
225 resistance (31%; all of which were heteroresistant) were missed by FT-MTBDR and, in people with
226 heteroresistance, multiple resistant strains were often present. Furthermore, 4) although the Ultra
227 heteroresistance probe pattern was associated with heteroresistance, this pattern had suboptimal
228 sensitivity and specificity for heteroresistance and was itself associated with Ultra false-resistant calls
229 (as was lower mycobacterial load). Lastly, 5) more than half of the individuals were rifampicin mono-
230 resistant, supporting the need for isoniazid DST. These data have implications for laboratory DST
231 algorithms, especially resolution of discordant results by different molecular methods.

232 Most rifampicin resistance discordance arose from MTBDR*plus* not detecting RAVs, rather than Ultra
233 falsely detecting RAVs. This might be because MTBDR*plus* interpretation is subjective even with the
234 semi-automated GenoScan and requires human reporting. In contrast, FT-MTBDR reporting is fully
235 automated. While FT-MTBDR identified most resistance missed by MTBDR*plus*, approximately half
236 of the isolates FT-MTBDR detected as rifampicin-susceptible had sequencing-detected resistance.
237 This contrasts with other studies that have reported FT-MTBDR sensitivities approaching 100%,²
238 however, these were done in Ultra rifampicin-resistant people (without specifically selecting the
239 discordant MTBDR*plus*-susceptible subset).

240 Heteroresistance, which we show to be a cause of Ultra-MTBDR*plus* discordance was, about a third
241 of the time, missed by FT-MTBDR. However, as these people were MTBDR*plus*-susceptible, FT-
242 MTBDR is still substantially better at detecting resistance than the previous generation technology.
243 Interestingly, within people with sequencing-detected heteroresistance, there was seldom one resistant
244 strain implicated, which is unexpected given that these are not samples taken from people on
245 treatment and sequencing was done after culture, which can result in loss of minority variants.⁸
246 Possible causes of this diversity include multiple exposures to rifampicin-resistant TB or substantial
247 intra-host evolution.

248 Certain probe patterns reported by Ultra have been proposed to be useful for diagnosing
249 heteroresistance,¹⁰ which may be clinically useful if first-line drugs could be included in the regimen
250 to rapidly reduce bacterial load of the drug-susceptible subpopulation.^{19, 20} However, in our study,
251 although this Ultra probe pattern was indeed associated with heteroresistance, it did not translate into
252 high sensitivity and specificity for heteroresistance. While FT-MTBDR does not currently offer a
253 heteroresistance readout, this feature could be incorporated into its software to potentially inform

254 treatment. Lastly, this Ultra heteroresistance pattern (as well as that from FT-MTBDR) was also
255 associated with Ultra false-resistance calls, as was the Ultra “very low” semi-quantitation category.
256 This category is a recognized risk factor for Xpert false-resistance,⁶ for which repeat testing is
257 recommended. Our data therefore suggests that samples with an Ultra heteroresistance pattern and or
258 “very low” bacterial load should be considered at increased risk for false-resistance. The utility of
259 repeat testing in such samples warrants further evaluation.

260 Our findings emphasize the importance of not assuming rifampicin-resistance equates to isoniazid
261 resistance, particularly in cases of discordant Ultra-MTBDR_{plus} results. Previous studies have
262 demonstrated 19%²¹ and 21%²² of Xpert rifampicin-resistant cases are isoniazid-susceptible by
263 MTBDR_{plus}. Our data therefore support the scale-up of upfront routine isoniazid DST to avoid the
264 inappropriate exclusion of isoniazid from regimens.

265 Our study has strengths and limitations. Ultra was done on specimens, while MTBDR_{plus}, FT-
266 MTBDR and SMOR were done on isolates. While this may be representative of some programmatic
267 algorithms, changes in subpopulation structures due to culture bias could create discordance.
268 Furthermore, phenotypic susceptibility testing was not possible as isolates were not stored to preserve
269 viability. However, SMOR has high sensitivity and specificity for phenotypic (and sub-phenotypic)
270 resistance.⁷ Another consideration is that our study was designed to investigate Ultra-resistant,
271 MTBDR_{plus}-susceptible discordance, rather than to assess Ultra rifampicin resistant calls in all
272 comers (which others have done for Ultra’s predecessor Xpert).⁶ In other words, our findings should
273 be interpreted within the context of samples pre-selected because they were Ultra-MTBDR_{plus}
274 discordant (such discordant samples are likely not representative of typical RAVs in our setting).

275 In conclusion, patients with Ultra rifampicin-resistant TB that were susceptible by MTBDR_{plus} are
276 predominantly truly rifampicin resistant unless Ultra produced a heteroresistant probe pattern or “very
277 low” semi-quantitation category (both associated with false Ultra rifampicin results). Isoniazid, for
278 which susceptibility testing should be done, likely remains useful in people with this Ultra-
279 MTBDR_{plus} discordance.

280 **Author Contributions**

281 All named authors were involved in conceptualization and design of the study. Y.G., A.A., G.B. and
282 E.A. assisted with specimen collection and specimen processing. F.N. M.F. and D.E. performed
283 SMOR testing. Y.G., G.T., E.A., R.V., M.F., F.N. and D.E. performed formal analysis, methodology
284 and writing original draft. All authors had full access to the de-identified data. All authors reviewed
285 and edited the manuscript and had final responsibility for the decision to submit for publication.

286 **Data Sharing**

287 Study data can be accessed on request from the corresponding author without restriction.

288 **Declaration of interests**

289 G.T. acknowledges funding from the EDCTP2 programme supported by the European Union
290 (RIA2018D-2509, PreFIT; RIA2018D-2493, SeroSelectTB; RIA2020I-3305, CAGE-TB) and the
291 National Institutes of Health (D43TW010350; U01AI152087; U54EB027049; R01AI136894). Y.G.
292 and R.W. acknowledges funding from the South African Medical Research Council. D.E.
293 acknowledges funding from the National Institutes of Health (R01AI131939).

294 **Acknowledgments**


295 The authors thank the National Health Laboratory (NHLS) as a source of data and the staff of
296 Greenpoint Tuberculosis Laboratory, NHLS, Cape Town, South Africa for assisting with collecting
297 samples. We would like to thank the staff from Clinical Mycobacteriology and Epidemiology
298 (CLIME) Group, Division of Molecular and Human Genetics, Stellenbosch University for their
299 support in performing FT-MTBDR. Hain-Bruker Lifesciences donated FT-MTBDR consumables and
300 loaned the GenoXtract fleXT and FluoroCyclerXT-96 equipment but had no other role in the study.
301 T-Gen provided instrumentation and reagents needed for SMOR processing.

302 **Figure legends**

303 **Figure 1. Study profile.** We quantified discordant rifampicin susceptibility results (Ultra-resistant,
304 MTBDR*plus*-susceptible) done at TB diagnosis on respiratory specimens over an 18-month period.
305 The distribution of HR is shown, and most isolates that were confirmed by sequencing have RAVs
306 missed by MTBDR*plus* but often detected by FT-MTBDR. Abbreviations: FT-MTBDR, FluoroType
307 MTBDR; MicroHR, microheteroresistance; MacroHR, macroheteroresistance; MTBC,
308 *Mycobacterium tuberculosis* complex; SMOR, single molecule-overlapping repeats; RAV, resistance-
309 associated variant; TB, tuberculosis; Ultra, Xpert MTB/RIF Ultra.

310 **Figure 2. Examples of an Ultra report generated by the GeneXpert software showing melt peak**
311 **temperatures for each amplicon.** (A) is a commonly seen rifampicin-resistant specimen with a
312 variant in the rpoB2 region. There is no indication of HR because, for rpoB2, “melt” has no value but
313 “mut melt” does (black arrows). In contrast, (B) has, for rpoB1, both “melt” and “mut melt” values,
314 suggesting HR. Abbreviations: °C; degree Celsius; HR, heteroresistance; melt, wild type melt peak
315 temperature; mut melt, mutant melt peak teak temperature; Ultra, Xpert MTB/RIF Ultra.

316 **Figure 1. Study Profile**



317

318

319 **Figure 2.**

A	<i>Analyte Name</i>		<i>Melting Peak Temperature (°C)</i>	B	<i>Analyte Name</i>		<i>Melting Peak Temperature (°C)</i>
	rpoB1 melt	—————→	69.6		rpoB1 melt	—————→	69.0
	rpoB2 melt				rpoB2 melt		72.9
	rpoB3 melt		75.6		rpoB3 melt		75.8
	rpoB4 melt		67.3		rpoB4 melt		67.1
	rpoB1 Mut melt				rpoB1 Mut melt	—————→	64.4
	rpoB2 Mut melt	—————→	68.7		rpoB2 Mut melt		
	rpoB3 Mut melt				rpoB3 Mut melt		
	rpoB4 Mut melt A				rpoB4 Mut melt A		
	rpoB4 Mut melt B				rpoB4 Mut melt B		

320

321

322

323 **Table 1.** Ultra parameters among true- and false-Ultra rifampicin-resistant results, in people who were
 324 MTBDR*plus*-susceptible, using SMOR on DNA from isolates as a reference standard. Ultra
 325 heteroresistance calls and lower detected bacillary load are more frequent among false-resistance
 326 results. Data are median (IQR) or % (n/N).

	True rifampicin-resistant (n=77)	False rifampicin-resistant (n=20)
C_{Tmin}	19 (18-25)	29 (27-31); p=0.0001
<i>Semi-quantitation category</i>		
High	40 (31/77)	5 (1/20); p=0.0028
Medium	31 (24/77)	15 (3/20); p=0.1506
Low	12 (9/77)	25 (5/20); p=0.1312
Very low	17 (13/77)	55 (11/20); p=0.0004
<i>Specific probes with mutation label</i>		
rpoB1 Mut	47 (32/68)	41 (7/17); p=0.6633
rpoB2 Mut	13 (9/68)	18 (3/17); p=0.6403
rpoB3 Mut	4 (3/68)	12 (2/17); p=0.2491
rpoB4 Mut A	13 (9/68)	12 (2/17); p=0.8716
rpoB4 Mut B	29 (2/68)	6 (1/17); p=0.5567
More than one MUT probe	19 (13/68)	12 (2/17); p=0.4769
<i>Ultra heteroresistance pattern</i>		
Heteroresistance pattern	32 (25/77)	60 (12/20); p=0.0239

327 Abbreviations: C_{Tmin}, cycle threshold minimum; HR, heteroresistance; MUT, mutation; Ultra, Xpert
 328 MTB/RIF Ultra. P-values are for within row comparisons across columns.

329

330 References

- 331 1. Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, et al. Mixed Mycobacterium
332 tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With
333 Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. *J Infect Dis.*
334 2018;218(12):1974-82.
- 335 2. Dippenaar A, Derendinger B, Dolby T, Beylis N, van Helden PD, Theron G, et al. Diagnostic
336 accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput
337 detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. *Clin*
338 *Microbiol Infect.* 2021;27(9):1351 e1- e4.
- 339 3. de Vos M, Derendinger B, Dolby T, Simpson J, van Helden PD, Rice JE, et al. Diagnostic
340 Accuracy and Utility of FluoroType MTBDR, a New Molecular Assay for Multidrug-Resistant
341 Tuberculosis. *J Clin Microbiol.* 2018;56(9).
- 342 4. Ghebrekristos Y. Characterization of Mycobacterium tuberculosis isolates with discordant
343 rifampicin susceptibility test results: University of Cape Town; 2018.
- 344 5. Beylis N, Ghebrekristos Y, Nicol M. Management of false-positive rifampicin resistant Xpert
345 MTB/RIF. *Lancet Microbe.* 2020;1(6):e238.
- 346 6. Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al.
347 Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective
348 observational study in Rwanda. *Lancet Microbe.* 2020;1(2):e74-e83.
- 349 7. Metcalfe JZ, Streicher E, Theron G, Colman RE, Allender C, Lemmer D, et al. Cryptic
350 Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance. *Am J Respir Crit*
351 *Care Med.* 2017;196(9):1191-201.
- 352 8. Metcalfe JZ, Streicher E, Theron G, Colman RE, Penaloza R, Allender C, et al. Mycobacterium
353 tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance.
354 *Antimicrob Agents Chemother.* 2017;61(11).
- 355 9. Engelthaler DM, Streicher EM, Kelley EJ, Allender CJ, Wiggins K, Jimenez D, et al. Minority
356 Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic
357 Resistance. *Am J Respir Cell Mol Biol.* 2019;61(6):789-91.
- 358 10. Chakravorty S, Simmons AM, Rownecki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert
359 MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an
360 Assay Suitable for Point-of-Care Testing. *mBio.* 2017;8(4).
- 361 11. Xpert® MTB/RIF Ultra (package insert) [Internet]. 2019 [cited 28 February 2023]. Available
362 from: https://www.biovendor.sk/download/30352/Manual_xpert_mtb-rif_ultra.pdf.
- 363 12. GenoType MTBDRplus VER 2.0 [Internet]. 2015 [cited February 2023]. Available from:
364 [https://www.hain-](https://www.hain-lifescience.de/include_datei/kundenmodule/packungsbeilage/download.php?id=936)
365 [lifescience.de/include_datei/kundenmodule/packungsbeilage/download.php?id=936](https://www.hain-lifescience.de/include_datei/kundenmodule/packungsbeilage/download.php?id=936).
- 366 13. GXT96 X2 Extraction Kit Version 1 (Package insert) [Internet]. 2022 [cited 2024-07-25].
367 Available from: <https://www.hain-lifescience.de/en/instructions-for-use.html>.
- 368 14. Kocagoz T, Yilmaz E, Ozkara S, Kocagoz S, Hayran M, Sachedeva M, et al. Detection of
369 Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified
370 procedure. *J Clin Microbiol.* 1993;31(6):1435-8.
- 371 15. Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, et al. Detection of Low-
372 Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon
373 Sequencing. *PLoS One.* 2015;10(5):e0126626.
- 374 16. Colman RE, Anderson J, Lemmer D, Lehmkühl E, Georghiou SB, Heaton H, et al. Rapid Drug
375 Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical
376 Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. *J Clin Microbiol.*
377 2016;54(8):2058-67.
- 378 17. Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R, et al. Bedaquiline
379 resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective
380 longitudinal cohort study. *Lancet Microbe.* 2023;4(12):e972-e82.

- 381 18. FluoroType MTBDR VER 2.0 (Package insert) [Internet]. Hain Lifescience (Brucker). 2024
382 [cited 2024-07-25]. Available from: <https://www.hain-lifescience.de/en/instructions-for-use.html>.
- 383 19. Department of Health (DOH) RoSA. Management of rifampicin resistant tuberculosis: A
384 Clinical reference guide. South Africa; 2020.
- 385 20. Health WCD. Clinical Guidelines & Standard Operating Procedure for the Implementation of
386 the Short & Long DR-TB regimens for Adults, Adolescents and Children. South Africa; 2018
387 September 2018.
- 388 21. Bisimwa BC, Nachega JB, Warren RM, Theron G, Metcalfe JZ, Shah M, et al. Xpert
389 Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate
390 for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and
391 Clinical Implications. Clin Infect Dis. 2021;73(2):e362-e70.
- 392 22. Pillay S, de Vos M, Derendinger B, Streicher EM, Dolby T, Scott LA, et al. Non-actionable
393 Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-
394 Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory. Clin
395 Infect Dis. 2023;76(3):e920-e9.
- 396